Find information on thousands of medical conditions and prescription drugs.

Retrolental fibroplasia

Retinopathy of prematurity (ROP), also known as retrolental fibroplasia (RLF), is a disease of the eye that affects prematurely born babies. It is thought to be caused by disorganised growth of retinal blood vessels resulting in scarring and retinal detachment. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
Gastroesophageal reflux...
Rabies
Radiophobia
Rasmussen's encephalitis
Raynaud's phenomenon
Reactive arthritis
Reactive hypoglycemia
Reflex sympathetic...
Regional enteritis
Reiter's Syndrome
Renal agenesis
Renal artery stenosis
Renal calculi
Renal cell carcinoma
Renal cell carcinoma
Renal cell carcinoma
Renal failure
Renal osteodystrophy
Renal tubular acidosis
Repetitive strain injury
Respiratory acidosis
Restless legs syndrome
Retinitis pigmentosa
Retinoblastoma
Retinoschisis
Retrolental fibroplasia
Retroperitoneal fibrosis
Rett syndrome
Reye's syndrome
Rh disease
Rhabdomyolysis
Rhabdomyosarcoma
Rheumatic fever
Rheumatism
Rheumatoid arthritis
Rickets
Rift Valley fever
Ringworm
Rocky Mountain spotted fever
Romano-Ward syndrome
Roseola infantum
Rubella
Rubeola
Rubinstein-Taybi syndrome
Rumination disorder
S
T
U
V
W
X
Y
Z
Medicines

ROP can be mild and may resolve spontaneously, but may lead to blindness in serious cases. Oxygen toxicity may contribute to the development of ROP.

International Classification of Retinopathy of Prematurity (ICROP)

The system used for described the findings of ROP is entitled, The International Classification of Retinopathy of Prematurity (ICROP). ICROP "demarcated the location of the disease into zones (1, 2, and 3) of the retina, the extent of the disease based on the clock hours (1-12), and the severity of the disease into stages (0-5)" .

Symptoms and prognosis

In preterm infants, the retina is often not fully formed. ROP occurs when abnormal tissue forms between the central and peripheral retina. There are 5 progressive stages to ROP. Stage 1 is mild and may resolve on its own without severe vision loss; stage 5 is severe and usually results in retinal detachment.

Multiple factors can determine how fast a patient progresses through the stages, including overall health, birth weight, the stage of ROP at initial diagnosis, and the presence or absence of "plus" disease. "Plus" disease occurs when the abnormal vessels in the retina invade other areas of the eye, greatly increasing the risk of retinal detachment.

The abnormal vessel growth often subsides spontaneously, but can progress to retinal detachment and vision loss in patients with extremely low birth weight. Patients with ROP are at greater risk for glaucoma, cataracts and myopia later in life, and should be examined yearly to help prevent and treat these conditions.

Treatment

  • Cryotherapy
  • "Indirect laser"
  • scleral buckle and/or vitrectomy may be considered for severe ROP with retinal detachment

Read more at Wikipedia.org


[List your site here Free!]


Drugs, Pregnancy, And Lactation
From OB/GYN News, 6/1/01 by Gerald G. Briggs

Antihistamines comprise a large, fairly diverse group of compounds that are so prevalent that many women are probably exposed to these drugs at some point during pregnancy.

In general, first-generation antihistamines are usually safe during pregnancy when used occasionally, but should not be used for frequent, chronic allergy symptoms. There is little human pregnancy information on second-generation antihistamines.

During the first trimester, it is best to avoid antihistamines. But if an antihistamine is indicated, the best option is the oral first-generation drug chlorpheniramine, which is marketed over the counter under several names, including Chlor-Trimeton. If an injectable antihistamine is indicated, diphenhydramine (Benadryl)would be the first choice.

Most published data on antihistamine use during pregnancy concern these two drugs and indicate that they are relatively safe when used occasionally. There have been no signals or clusters of birth defects found in multiple studies of these agents.

The three second-generation antihistamines--cetirizine (Zyrtec), loratadine (Claritin), and fexofenadine (Allegra)--have not been shown to be teratogenic in animals. Nevertheless, they should be avoided if possible during the first trimester because of the sparse amount of data in humans on use of these drugs during pregnancy These data include a 1997 study of pregnant women that found no significant difference in the rates of major or minor malformations, gestational age at delivery, birth weight, or neonatal distress among 39 women who took cetirizine (most included first-trimester use), 81 women who took hydroxyzine (Vistaril or Atarax), and 110 controls who did not take either agent.

In a 1998 study of 18 women who took loratadine during the first trimester, 16 had normal infants with no major malformations; the other two had elective abortions. But this study is small and did not look for minor malformations. Loratadine is considered by many authors to be an acceptable alternative to a first-generation antihista mine, except during the first trimester.

To date, there have been no reports of human pregnancies exposed to Allegra, but problems with implantation have been reported in rats administered three times the human dose.

Neonatal withdrawal symptoms have been reported rarely in conjunction with commonly used antihistamines when used continuously during pregnancy, with the most cases reported for diphenhydramine. A woman who took 150 mg a day of diphenhydramine throughout pregnancy gave birth to a baby who developed withdrawal symptoms on the fifth day of life. Hydroxyzine has also been reported to cause withdrawal symptoms in newborns.

Diphenhydramine also has dose-related oxytocic properties and, if administered intravenously during labor, can stimulate the uterus.

A drug interaction between diphenhydramine (50 mg) and the sleeping medication temazepam (Restoril 30mg) may have led to the stillbirth of a term fetus. The mechanism of the interaction is unknown, but a high fetal death rate was confirmed in one animal study when the two drugs were combined.

A significantly increased risk of retrolental fibroplasia in premature babies whose mothers had taken a first-generation antihistamine during the last 2 weeks of gestation was also found in a 1986 multicenter study of premature newborns. This defect has not been re ported in full-term babies exposed to antihistamines in utero.

All antihistamines are excreted in breast milk, but there is little information on these drugs during lactation, particularly for second-generation agents.

Irritability and drowsiness in nursing infants are potential complications, and lactating mothers taking antihistamines should watch their infants for these ad verse effects. In one case with clemastine (Tavist), the infant also had neck stiffness and high-pitched crying.

In a study of loratadine, the drug and its metabolites were detected in the milk of six women who took four times the recommended dose. The author estimated that the infants received about 0.5% of their mother's total dose and concluded that there appeared to be little risk to the exposed infants. This was a one-time dose, and again, the message of this study is that occasion al use of these drugs during lactation does not seem to present a major risk, if any, but may cause problems when taken routinely.

GERALD G. BRIGGS is clinical pharmacist, Women's Hospital, Long Beach Memorial Medical Center; clinical professor of pharmacy, University of California, San Francisco.

COPYRIGHT 2001 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Retrolental fibroplasia
Home Contact Resources Exchange Links ebay